ACRV
ACRV
NASDAQ · Biotechnology

Acrivon Therapeutics Inc

$1.67
+0.07 (+4.38%)
As of Feb 8, 2:18 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 27.49M 26.17M 29.17M
Net Income -6,413,122 -6,638,758 -7,979,028
EPS
Profit Margin -23.3% -25.4% -27.4%
Rev Growth +12.4% +6.3% +17.3%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 11.18M 10.69M 11.61M
Total Equity 38.40M 43.20M 43.28M
D/E Ratio 0.29 0.25 0.27
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -10,041,478 -10,799,684 -11,152,703
Free Cash Flow -6,132,912 -6,792,749 -5,207,622